云顶新耀(01952)发布公告，中国国家药品监督管理局(NMPA)已批准维适平®(精氨酸艾曲莫德片, VELSIPITY®)的新药上市申请(新药上市申请)，在中国用于治疗对传统治疗或生物制剂应答不充分、失 应答或不耐受的中度至重度活动性溃疡性结肠炎(UC)成人患者。 作为新一代高选择性鞘氨醇-1-磷酸(S1P)受体调节剂，维适平®每日一次口服，可实现快速起效和强效 深度黏膜癒合，并具有良好的安全性特征，为成人溃疡性结肠炎患者提供新的一线治疗选择。维适平® 此次获批，是基于亚洲多中心III期注册临床ENLIGHT UC研究(ES101002)的结果和全球III期注册研究 ELEVATE UC(包括ELEVATE UC 52和ELEVATE UC 12研究)的结果。ENLIGHT UC研究是迄今完成的最 大规模亚洲中重度活动性溃疡性结肠炎患者的III期注册临床研究，总计纳入340名患者。在12周诱导期 及40周维持期治疗中，维适平®治疗组在所有主要和次要疗效终点上均达到统计学显著性与临床意义， 且安全性良好，安全性特征与既往研究一致。ELEVATE UC III期注册研究中的ELEVATE UC 52和 ELEV ...

Group 1 - Lee & Man Paper (02314) has seen its stock price rise by over 30% year-to-date, with expected profits of approximately HKD 1.88 billion to HKD 2.00 billion in 2025, representing a year-on-year growth of 38% to 47% due to increased marginal profits [1] - Soundon Technology (02495) shares rose over 8.8% after winning a contract worth nearly RMB 300 million for an AI project in Sichuan province [1] - Zhongxin Innovation (03931) stock increased by over 3.8%, with a reported 630% year-on-year growth in commercial battery deliveries in January 2026, indicating a strong market strategy and capacity layout [1] Group 2 - Tea stocks experienced a rise, with Gu Ming (01364) up 4.12%, Cha Bai Dao (02555) up 3.74%, and others benefiting from a promotional campaign offering free milk tea at over 300,000 stores nationwide [2] - Innovent Biologics (09969) shares surged over 11% after announcing expected revenues of RMB 2.37 billion in 2025, a 134% increase, and a projected net profit of around RMB 630 million [2] - Jun Da Holdings (02865) rebounded over 4.6% following news of the U.S. Federal Communications Commission accepting SpaceX's data center application [2] Group 3 - Li Auto-W (02015) shares rose over 5.3% as the CEO teased the new Li L9 model, emphasizing the importance of AI in enhancing vehicle value [3] - JX International Resources (03858) saw a stock increase of over 4.6% as tungsten prices reached a recent high of CNY 1,545,000 per ton, up CNY 25,000 from the previous trading day [3] - Nine Dragons Paper (02689) shares increased by over 5.7% after announcing a profit forecast for FY26H1 of CNY 2.15 billion to CNY 2.25 billion, a year-on-year growth of 216% to 231% [3] Group 4 - Long Resources (01712) stock surged over 35%, reaching a historical high, with expected after-tax profits of AUD 58 million to AUD 62 million for the year ending December 31, 2025, a significant increase from AUD 12.9 million in the previous year [4] Group 5 - Forgent Power Solutions (FPS.US) debuted on the U.S. stock market with a closing increase of 7.41%, focusing on power solutions for data centers [5] - Bob's Discount Furniture (BOBS.US) also entered the market, with a slight increase of 0.12%, managing 206 showrooms across 26 states and projecting revenues of USD 2.32 billion for FY2025 [5] Group 6 - Eikon Therapeutics (EIKN.US) fell over 16.67% on its Nasdaq debut, focusing on cancer therapies with a candidate drug in mid-stage trials [6] - Cryptocurrency stocks saw significant declines, with Hut 8 (HUT.US) down 17.89% and others following suit amid a Bitcoin sell-off, which dropped nearly 10% [6] Group 7 - Major U.S. indices opened lower, with the Nasdaq down 1.6%, and notable tech stocks like Amazon (AMZN.US) and Tesla (TSLA.US) also declining [7] - Estée Lauder (EL.US) dropped nearly 19.19% despite meeting sales expectations, reflecting market volatility [7] Group 8 - NIO (NIO.US) shares rose 5.86% after announcing an expected adjusted operating profit of between RMB 700 million and RMB 1.2 billion for Q4 2025, marking its first quarterly adjusted operating profit [8] - Hims & Hers Health (HIMS.US) initially surged nearly 14% before closing down 3.77%, launching a new generic medication at a competitive price [9] - Qualcomm (QCOM.US) fell 8.46% amid concerns over weak earnings forecasts related to chip shortages affecting smartphone demand [9]

Core Viewpoint - The approval of VELSIPITY® (Arginine Acquimod Tablets) by the NMPA marks a significant milestone for the company in establishing its leading position in the autoimmune field, providing a new first-line treatment option for adult patients with moderate to severe active ulcerative colitis who have inadequate response to traditional therapies or biologics [1][3] Group 1: Product Approval and Clinical Research - VELSIPITY® is a next-generation high-selectivity sphingosine-1-phosphate (S1P) receptor modulator, administered once daily, demonstrating rapid onset and strong mucosal healing efficacy with good safety characteristics [2] - The approval is based on results from the ENLIGHT UC study, the largest Phase III registration clinical trial for moderate to severe active ulcerative colitis patients in Asia, involving 340 patients, achieving statistical significance and clinical relevance in all primary and secondary efficacy endpoints [2] - The ELEVATE UC Phase III studies further validated the benefit-risk profile of VELSIPITY®, with ELEVATE UC 52 and ELEVATE UC 12 being randomized, double-blind, placebo-controlled trials [2] Group 2: Commercialization Strategy - The company is preparing for the commercialization of VELSIPITY® and aims to expedite its availability to domestic patients while actively promoting its inclusion in the national medical insurance catalog [3] - The approval aligns with the company's 2030 development strategy, which emphasizes a dual approach of "BD collaboration + self-research" to create certain value through commercialization and growth through research and development [3][5] - The company plans to establish a comprehensive commercialization system and aims to achieve revenue exceeding 10 billion RMB by 2028 and over 15 billion RMB by 2030, with a projected compound annual growth rate of over 50% from 2025 to 2030 [4] Group 3: Future Growth and Globalization - The 2030 development strategy signifies a critical milestone for the company in advancing to the forefront of global biopharmaceuticals, focusing on a product portfolio that captures blue ocean opportunities [5] - The company intends to introduce 3 to 5 late-stage blockbuster products annually and aims to contribute 6 billion RMB in revenue from over 20 high-value assets by 2030, with a long-term goal of approximately 30 billion RMB by 2035 [5] - The company is also initiating a globalization strategy to enhance its global registration and clinical development capabilities, aiming for accelerated international growth through a dual engine of "overseas licensing + commercialization" [4]

值得注意的是，嘉和生物上月宣布，拟不时于公开市场购回公司股份。公司自1月28日起连续多日回购 股份，截至2月5日，公司累计回购金额约1851.7万港元，累计回购724.5万股股份。 消息面上，12月30日，亿腾医药以反向收购方式完成与嘉和生物的换股合并和上市。 此次反向收购的 达成，标志着亿腾嘉和的正式成立，并在战略整合与发展上迈入全新阶段。嘉和生物-B中文股份简称则 由"嘉和生物"更改为"亿腾嘉和"，自2026年2月6日起上午九时正起生效。 智通财经APP获悉，亿腾嘉和(06998)午前涨超9%，截至发稿，涨8.68%，报2.88港元，成交额692.59万 港元。 ...

Core Viewpoint - Goldman Sachs has raised the earnings per share (EPS) forecasts for Innovent Biologics (01801) for 2025 to 2027, reflecting a positive outlook on the company's financial performance despite some challenges in the market [1] Financial Performance - The product revenue for Innovent Biologics in the fourth quarter of last year was approximately 3.3 billion RMB, meeting Goldman Sachs' expectations, with a year-on-year growth of 60% from a relatively low base, remaining flat quarter-on-quarter [1] - The company's new product portfolio continues to show growth, with a quarterly increase of 13%, which offsets the weak performance of Tyvyt [1] - For the full year of 2025, product sales are expected to be strong, with a projected year-on-year growth of 45% to 11.9 billion RMB, marking the first time sales exceed the 10 billion RMB milestone, driven primarily by the growth in the biopharmaceutical business [1] Target Price and Rating - The target price for Innovent Biologics has been adjusted to 102.85 HKD from the previous 107.96 HKD, while maintaining a "Buy" rating [1]

Core Viewpoint - Goldman Sachs has raised the earnings per share forecast for Innovent Biologics (01801) for 2025 to 2027, with target prices adjusted to HKD 102.85 from HKD 107.96, maintaining a "Buy" rating [1] Group 1: Earnings Forecast - The earnings per share estimates for Innovent Biologics have been increased to HKD 0.62, HKD 1.74, and HKD 2.54 for the years 2025, 2026, and 2027 respectively, up from HKD 0.54, HKD 1.43, and HKD 2.49 [1] - The company is expected to achieve a strong product sales performance in 2025, with a projected year-on-year growth of 45% to reach RMB 11.9 billion, marking a significant milestone of surpassing RMB 10 billion [1] Group 2: Revenue Performance - In the fourth quarter of the previous year, the product revenue was approximately RMB 3.3 billion, aligning with Goldman Sachs' expectations, and reflecting a year-on-year growth of 60% from a relatively low base, while remaining flat quarter-on-quarter [1] - The new product portfolio continues to show growth momentum, with a quarterly increase of 13%, which offsets the weak performance of Tyvyt [1]

Group 1 - The core point of the news is that Shuyou Shen's stock price has increased by 5.65% on February 6, reaching 29.00 CNY per share, with a total market capitalization of 13.855 billion CNY and a trading volume of 437 million CNY, marking a cumulative increase of 10.2% over three consecutive days [1] - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue composition of Shuyou Shen includes 59.17% from injectable mouse nerve growth factor (Sutai Shen), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - According to data, CITIC Prudential Fund has a significant holding in Shuyou Shen, with the CITIC Prudential Zhi Rui Mixed A Fund (003432) increasing its holdings by 60,000 shares in the fourth quarter, totaling 355,000 shares, which represents 4% of the fund's net value [2] - The fund has generated a floating profit of approximately 550,300 CNY today and a total of 901,700 CNY during the three-day increase [2] - The CITIC Prudential Zhi Rui Mixed A Fund was established on October 21, 2016, with a current size of 134 million CNY, and has achieved a year-to-date return of 0.45% [2]

Core Viewpoint - The company, Fuhong Hanlin, has seen a significant stock price increase following the announcement of a licensing agreement for its PD-1 monoclonal antibody, Hanshu (Surulitinib), with Eizai in Japan, indicating positive market sentiment towards the deal [1] Group 1: Licensing Agreement Details - Fuhong Hanlin announced that it will license the rights of its PD-1 monoclonal antibody, Hanshu, to Eizai in Japan [1] - Eizai will pay an upfront fee of $75 million to Fuhong Hanlin, along with potential regulatory milestone payments of up to $80.01 million and sales milestone payments of up to $233.3 million [1] - Additionally, Fuhong Hanlin will receive a double-digit percentage royalty based on product sales [1] Group 2: Product Information - Surulitinib is an innovative PD-1 monoclonal antibody developed by Fuhong Hanlin [1] - In China, Surulitinib has been approved for multiple indications, including squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsqNSCLC), and esophageal squamous cell carcinoma (ESCC) [1] - In the European Union, Surulitinib has been approved for the ES-SCLC indication and is the first PD-1 monoclonal antibody approved for first-line treatment of ES-SCLC globally [1]

Core Viewpoint - The announcement of the licensing agreement for the anti-PD-1 monoclonal antibody H drug, Hansuzhu (SruLi monoclonal antibody), to Eisai has positively impacted the stock price of Fuhong Hanlin, reflecting investor confidence in the potential revenue from this partnership [1] Group 1: Financial Terms of the Agreement - Eisai will pay Fuhong Hanlin an upfront payment of $75 million [1] - Additional regulatory milestone payments could reach up to $80.01 million [1] - Sales milestone payments could total up to $233.3 million, along with a double-digit percentage royalty based on product sales [1] Group 2: Product Information - SruLi monoclonal antibody is an innovative anti-PD-1 monoclonal antibody developed by Fuhong Hanlin [1] - In China, SruLi has been approved for multiple indications, including squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsqNSCLC), and esophageal squamous cell carcinoma (ESCC) [1] - In the European Union, SruLi has been approved for the ES-SCLC indication and is the first anti-PD-1 monoclonal antibody approved for first-line treatment of ES-SCLC globally [1]

Core Viewpoint - The demand for safer and more effective rabies vaccines is increasing due to a rise in rabies cases and deaths, highlighting the urgency for innovative solutions in the market [1][2]. Group 1: Product Development - Aimee Vaccine's serum-free iterative rabies vaccine has successfully passed clinical trial inspections by the National Medical Products Administration, indicating it is closer to market launch [1]. - The Phase III clinical trial results show that the serum-free iterative rabies vaccine has good safety, immunogenicity, and durability, meeting all preset evaluation standards [1]. - Unlike traditional rabies vaccines, Aimee's serum-free vaccine does not contain animal serum, significantly improving safety and reducing adverse reactions [1]. Group 2: Market Context - Rabies remains a severe public health challenge globally, with approximately 40 million people exposed to rabies in China each year, and the vaccination rate for exposed individuals is only about 35% [2]. - After four consecutive years of decline, rabies cases and deaths in China are projected to rise again starting in 2024, with 244 reported cases and 233 deaths in 2025, marking the highest figures since 2020 [2]. - The increase in rabies cases indicates a persistent and urgent need for upgraded rabies vaccines in the market [2]. Group 3: Market Position and Strategy - Aimee Vaccine is the second-largest rabies vaccine producer globally, with a comprehensive product matrix covering various technologies, including serum-free and mRNA vaccines, positioning the company as a dominant player in the domestic market [2]. - The company has established a sales network covering all 31 provinces in China, facilitating rapid market penetration for new products [3]. - Aimee Vaccine is also expanding into international markets, exporting rabies vaccines to emerging markets such as Pakistan, Egypt, Tajikistan, and Côte d'Ivoire, which may provide new growth opportunities [3]. Group 4: Financial Outlook - Aimee Vaccine is entering a critical phase with the upcoming launch of innovative products, supported by its strong R&D, production, and commercialization capabilities [4]. - Analysts predict the company's net profit could reach 883 million yuan and 1.52 billion yuan by 2027, indicating potential for significant growth as multiple innovative vaccines enter the market [4]. - The company is expected to play an increasingly important role in both the domestic and global high-end vaccine markets as it achieves substantial performance growth [4].